More than 80 U.S. lawmakers asked the FDA to stop counterfeit GLP-1 drugs linked to Chinese suppliers from entering the ...

Both Eli Lilly LLY and Merck MRK are major players in the U.S. pharmaceutical industry, developing and commercializing ...

Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some positive developments at rival Novo Nordisk NVO were the primary reasons ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Now, it’s worth noting Stock Advisor ’s total average return is 998 % — a market-crushing outperformance compared to 174 % for the S&P 500. Don’t miss out on the latest top 10 list ...

Zepbound brought in $2.3 billion in U.S. sales during this year’s first quarter, ... Those could hit the market in the next year or so, ... She says competition like this, ...

Despite a short time on the market, Mounjaro and Zepbound have become key top-line drivers for Lilly in 2024, with demand rising rapidly. ... Competition Heating Up in Obesity Space.

Novo Nordisk is facing fierce competition from obesity rival Zepbound, ... where Novo’s GLP-1 products hold a 70% market share. Diabetes med Ozempic leads the charge with 47% of that.

As demand soars for weight loss medications, so has the competition. Eli Lilly slashed prices for its hugely successful obesity medication, Zepbound. This comes at a time when compounded GLP-1 ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.